Related Experiment Video
Updated: May 30, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy
Thomas Danne1, Olga Kordonouri, Martin Holder
1Children's Hospital on the Bult, Hannover, Germany. danne@hka.de
Diabetes Technology & Therapeutics
|August 11, 2011
Summary
Sensor-augmented pump therapy with low glucose suspend (LGS) significantly reduces hypoglycemia frequency in children and adolescents with type 1 diabetes. This advanced insulin pump feature improves glycemic control without compromising safety.
Area of Science:
- Pediatrics
- Endocrinology
- Diabetology
Background:
- Severe hypoglycemia is a significant challenge in managing type 1 diabetes.
- Sensor-augmented pump (SAP) therapy, incorporating low glucose suspend (LGS), offers a potential solution to mitigate hypoglycemia.
- This study evaluated the real-world effectiveness of LGS in pediatric patients.
Purpose of the Study:
- To investigate the impact of the LGS algorithm on the frequency of hypoglycemic episodes in children and adolescents with type 1 diabetes.
- To assess the safety and efficacy of SAP with LGS under real-life conditions.
Main Methods:
- A prospective study involving 21 pediatric patients with type 1 diabetes.
- Patients used the Paradigm(®) Veo(™) system in two phases: SAP without LGS (2 weeks) and SAP with LGS (6 weeks).
- Hypoglycemia frequency was assessed with LGS set to shut off insulin for up to 2 hours when sensor glucose dropped below 70 mg/dL (3.9 mmol/L).
Main Results:
- The number of hypoglycemic excursions per day was significantly reduced with SAP+LGS (P=0.010 for <70 mg/dL, P=0.005 for ≤40 mg/dL).
- Time spent in hypoglycemia decreased significantly (average minutes/day, P=0.002).
- No severe hyperglycemia or diabetic ketoacidosis events occurred following LGS activation, indicating maintained safety.
Conclusions:
- Sensor-augmented pump therapy with the low glucose suspend feature effectively reduces hypoglycemia frequency in pediatric patients with type 1 diabetes.
- The LGS algorithm demonstrates a favorable safety profile, without increasing the risk of severe hyperglycemia or diabetic ketoacidosis.
- SAP with LGS is a valuable tool for improving glycemic control and reducing hypoglycemia burden in young individuals with type 1 diabetes.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...